OPIANT PHARMACEUTICALS, INC. Quarterly Liabilities in USD from Q2 2011 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
Summary
Opiant Pharmaceuticals, Inc. quarterly Liabilities history and growth rate from Q2 2011 to Q3 2022.
  • Opiant Pharmaceuticals, Inc. Liabilities for the quarter ending September 30, 2022 was $21.4M, a 20.5% decline year-over-year.
Liabilities, Quarterly (USD)
Liabilities, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2022 $21.4M -$5.53M -20.5% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $19.2M -$6.17M -24.3% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $21.1M -$3.86M -15.5% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $23.6M -$1.53M -6.1% Dec 31, 2021 10-Q 2022-11-14
Q3 2021 $27M +$20.3M +303% Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $25.4M +$20.3M +394% Jun 30, 2021 10-Q 2021-08-05
Q1 2021 $24.9M +$20.5M +459% Mar 31, 2021 10-Q 2021-05-11
Q4 2020 $25.1M +$19.3M +328% Dec 31, 2020 10-K 2022-03-15
Q3 2020 $6.7M -$3.06M -31.4% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 $5.14M -$3.62M -41.3% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 $4.46M -$5.01M -52.9% Mar 31, 2020 10-Q 2020-05-12
Q4 2019 $5.86M -$6.66M -53.2% Dec 31, 2019 10-K 2021-03-04
Q3 2019 $9.76M +$5.63M +136% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $8.76M +$2.35M +36.6% Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $9.47M +$1.65M +21.1% Mar 31, 2019 10-Q 2019-05-09
Q4 2018 $12.5M +$4.75M +61.2% Dec 31, 2018 10-K 2020-03-04
Q3 2018 $4.13M -$2.62M -38.9% Sep 30, 2018 10-Q 2018-11-07
Q2 2018 $6.42M -$57.5K -0.89% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 $7.82M +$2.3M +41.8% Mar 31, 2018 10-Q 2018-05-08
Q4 2017 $7.77M +$726K +10.3% Dec 31, 2017 10-K 2019-03-21
Q3 2017 $6.75M -$352K -4.95% Oct 31, 2017 10-Q 2017-12-04
Q2 2017 $6.47M -$113K -1.72% Jul 31, 2017 10-K 2019-03-21
Q1 2017 $5.52M -$655K -10.6% Apr 30, 2017 10-Q 2017-06-14
Q4 2016 $7.05M +$814K +13.1% Jan 31, 2017 10-Q 2017-03-15
Q3 2016 $7.1M -$2.61M -26.9% Oct 31, 2016 10-Q 2016-12-15
Q2 2016 $6.59M -$2.29M -25.8% Jul 31, 2016 10-KT 2018-03-07
Q1 2016 $6.17M -$2.09M -25.3% Apr 30, 2016 10-Q 2016-06-08
Q4 2015 $6.23M -$881K -12.4% Jan 31, 2016 10-Q 2016-03-15
Q3 2015 $9.71M +$4.37M +81.9% Oct 31, 2015 10-Q 2015-12-14
Q2 2015 $8.87M +$5.5M +163% Jul 31, 2015 10-K 2016-10-28
Q1 2015 $8.26M +$5.76M +230% Apr 30, 2015 10-Q 2015-06-12
Q4 2014 $7.11M +$4.96M +231% Jan 31, 2015 10-Q 2015-03-17
Q3 2014 $5.34M +$3.14M +143% Oct 31, 2014 10-Q 2014-12-09
Q2 2014 $3.38M +$1.75M +107% Jul 31, 2014 10-K 2015-10-26
Q1 2014 $2.5M +$1.32M +111% Apr 30, 2014 10-Q 2014-06-10
Q4 2013 $2.15M +$946K +78.6% Jan 31, 2014 10-Q 2014-03-17
Q3 2013 $2.2M +$1.34M +154% Oct 31, 2013 10-Q 2013-12-16
Q2 2013 $1.63M +$969K +146% Jul 31, 2013 10-K 2014-10-27
Q1 2013 $1.19M +$655K +123% Apr 30, 2013 10-Q 2013-06-14
Q4 2012 $1.2M +$835K +227% Jan 31, 2013 10-Q 2013-03-18
Q3 2012 $865K +$596K +221% Oct 31, 2012 10-Q 2012-12-20
Q2 2012 $664K +$247K +59.5% Jul 31, 2012 10-K 2013-10-29
Q1 2012 $534K Apr 30, 2012 10-Q 2012-06-14
Q4 2011 $368K Jan 31, 2012 10-Q 2012-03-16
Q3 2011 $270K Oct 31, 2011 10-Q 2011-12-15
Q2 2011 $416K Jul 31, 2011 10-K/A 2012-11-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.